Products for Research Use Only

Multi-kinase-IN-4

CAT: 0804-HY-149407Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-149407Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM) . Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer[1].
UNSPSC
12352005
Target
Apoptosis; CDK; EGFR; Necroptosis; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/multi-kinase-in-4.html
Solubility
10 mM in DMSO
Smiles
O=C1N(C/C=C(CC)\C)C(SCC2=CC=C(Cl)C=C2)=NC3=C1C=C(F)C=C3
Molecular Formula
C21H20ClFN2OS
Molecular Weight
402.91
References & Citations
[1]Ali Altharawi, et al. Novel 2-Sulfanylquinazolin-4 (3H) -one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules. 2023 Jul; 28 (14) : 5548.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2; ErbB2/HER2; VEGFR2/KDR/Flk-1